CD274 and gastric cancer: For example, although PD-1/PD-L1 has emerged as a potential immune marker for prognosis and predictions in a range of malignancies, the overall response rate of anti-PD-1/PD-L1 treatment in GC was only about 12% 12-13 and some patients even developed hyper-progressive disease (HPD).